| 治疗纯合子型家族性高胆固醇血症新药:evinacumab |
| |
| 引用本文： | 高清,刘建立,王作军. 治疗纯合子型家族性高胆固醇血症新药:evinacumab[J]. 中国新药与临床杂志, 2022, 0(1): 20-23 |
| |
| 作者姓名： | 高清 刘建立 王作军 |
| |
| 作者单位： | 临朐县人民医院功能检查科;潍坊医学院附属医院心内科 |
| |
| 摘 要： | 纯合子型家族性高胆固醇血症(HoFH)是一种罕见的低密度脂蛋白胆固醇(LDL-C)水平异常高的遗传性疾病.血管生成素样蛋白3(ANGPTL3)是治疗高脂血症的新靶点,evinacumab(Evi)是ANGPTL3抑制剂.Evi于2021年2月被美国食品和药物管理局批准上市,作为其他降低LDL-C疗法的辅助药物,用于治疗...
|
| 关 键 词： | evinacumab 家族性高胆固醇血症 血管生成素样蛋白质类 胆固醇,LDL |
A new drug in treating homozygous familial hypercholesterolemia:evinacumab |
| |
| GAO Qing,LIU Jian-li,WANG Zuo-jun. A new drug in treating homozygous familial hypercholesterolemia:evinacumab[J]. Chinese Journal of New Drugs and Clinical Remedies, 2022, 0(1): 20-23 |
| |
| Authors: | GAO Qing LIU Jian-li WANG Zuo-jun |
| |
| Affiliation: | (Functional Examination Room,the People’s Hospital of Linqu,Linqu SHANDONG 262600,China;Department of Cardiology,Affiliated Hospital of Weifang Medical University,Weifang SHANDONG 262700,China) |
| |
| Abstract: | Homozygous familial hypercholesterolemia(HoFH)is a rare hereditary disorder,pathophysiologically featuring the abnormally increased serum low-density lipoprotein cholesterol(LDL-C).Angiopoietin-like 3 protein(ANGPTL3)is the new therapeutic target for hyperlipidemia.Evinacumab(Evi)is an ANGPTL3 inhibitor approved by U.S.Food and Drug Administration in February 2021 as an adjunct to other LDL-C lowering therapies for the treatment of adult and pediatric patients,aged 12 years and older with HoFH.Current clinical trials have demonstrated that evinacumab is effective for lowering LDL-C in patients with HoFH,and a common adverse reaction is nasopharyngitis. |
| |
| Keywords: | evinacumab familial hypercholesterolemias angiopoietin-like proteins cholesterol,LDL |
| 本文献已被 维普 等数据库收录！ |
